Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RIVA-PCI Registry - Prospective Registry of Rivaroxaban in Patients With Atrial Fibrillation

NCT03315650 is registered in ClinicalTrials.gov with IHF GmbH - Institut für Herzinfarktforschung as lead sponsor.

NCT NCT03315650
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03315650 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RIVA-PCI Registry - Prospective Registry of Rivaroxaban in Patients With Atrial Fibrillation
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Phase
Observational
Overall status
Completed
Start date
January 1, 2018
Completion date
June 24, 2021
Enrollment
1,632 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

acute coronary syndrome, antithrombotic therapy, non-valvular atrial fibrillation, percutaneous coronary intervention